Changes in lognormal shape parameter guide design of patient-specific radiochemotherapy cocktails

Journal of Nuclear Medicine

Volumn 52, Issue 4, 2011, Pages 642-649

  Akudugu, John M ^a   Neti, Prasad V S V ^a   Howell, Roger W ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Daunomycin; Doxorubicin; Flow cytometry; Lognormal; Polonium 210; Radiobiology dosimetry; Radionuclide therapy

Indexed keywords

CITRATE PO 210; DAUNORUBICIN; DOXORUBICIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL POPULATION; CELL SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG RESPONSE; DRUG UPTAKE; FLOW CYTOMETRY; IONIZING RADIATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ALGORITHMS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CITRIC ACID; CRICETINAE; CRICETULUS; DAUNORUBICIN; DOXORUBICIN; DRUG COMBINATIONS; DRUG DESIGN; POLONIUM; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 79954609863     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083584     Document Type: Article

References (39)

1. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/ paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006;103:155-159. (Pubitemid 44374683)
2. Trodella L, Marinis FD, D'Angelillo RM, et al. Induction cisplatin-gemcitabinepaclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. Lung Cancer 2006;54:331-338. (Pubitemid 44637201)
3. Chen S-W, Liang J-A, Hung Y-C, et al. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: A control cohort comparison with radiation alone on treatment outcome and complications. Int J Radiat Oncol Biol Phys. 2006;66:1370-1377.
4. Numico G, Russi EG, Vitiello R, et al. Gemcitabine and cisplatin in a concomitant alternating chemotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided schedule. Int J Radiat Oncol Biol Phys. 2006;66: 731-737. (Pubitemid 44436711)
5. Howell RW, Kassis AI, Adelstein SJ, et al. Radiotoxicity of 195mPt labeled transplatinum( II) in mammalian cells. Radiat Res. 1994;140:55-62. (Pubitemid 24325164)
6. O'Donnell RT, DeNardo SJ, Miers LA, et al. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm. 1998;13:351-361. (Pubitemid 29011307)
7. Blum RH, Cooper J, Schmidt AM, et al. Cisplatin and vinblastine chemotherapy for metastatic non-small cell carcinoma followed by irradiation in patients with regional disease. Cancer Treat Rep. 1986;70:333-337. (Pubitemid 16130210)
8. Dyduch M, Skolyszewski J, Korzeniowski S, Sokolowski A. Analysis of treatment results in advanced Hodgkin's disease: The case for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:634-643. (Pubitemid 36677355)
9. Komaki R, Scott CB, Sause WT, et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys.1997;39:537-544. (Pubitemid 27441416)
10. Śmid L, Budihna M, Zakotnik B, et al. Postoperative concomitant irradiation and chemotherapy with mitomycin c and bleomycin for advanced head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:1055-1062. (Pubitemid 36794037)
11. Akudugu JM, Slabbert JP. Modulation of radiosensitivity in Chinese hamster lung fibroblasts by cisplatin. Can J Physiol Pharmacol. 2008;86:257-263. (Pubitemid 351705486)
12. Mulatero C, McClaren BR, Mason M, Oliver RTD, Gallagher CJ. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma. Br J Cancer. 2000;83:1612-1616. (Pubitemid 32001702)
13. Milenic DE, Garmestani K, Brady ED, et al. Multimodality therapy: Potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res. 2008;14:5108-5115.
14. Mokaleng BB, Akudugu JM. Modulation of the sensitivity in Chinese hamster cells to photons and fast neutrons by cisplatin, vinblastine, and bleomycin. Can J Physiol Pharmacol. 2009;87:347-352.
15. Williams LE, Duda RB, Proffitt RT, et al. Tumor uptake as a function of tumor mass: A mathematic model. J Nucl Med. 1988;29:103-109. (Pubitemid 18043002)
16. Behr TM, Behe M, Lohr M, et al. Therapeutic advantages of Auger electronover beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med. 2000;27:753-765. (Pubitemid 30456758)
17. Jönsson B-A, Strand S-E, Emanuelsson H, Larsson B. Tissue, cellular, and subcellular distribution of indium radionuclides in the rat. In: Howell RW, Narra VR, Sastry KSR, Rao DV, eds. Biophysical Aspects of Auger Processes. Woodbury, NY: American Institute of Physics; 1992:249-272. Available at: Http://www. aapm.org/pubs/books/PROC-8.pdf. Accessed February 18, 2011.
18. Makrigiorgos GM, Baranowska-Kortylewicz J, Van den Abbeele AD, et al. Microscopic spatial inhomogeneity of radiopharmaceutical deposition in mammalian tissues: Dosimetry at the cellular level and comparison with conventional dosimetry. Radiat Prot Dosimetry. 1990;31:319-324. (Pubitemid 20286753)
19. Howell RW, Neti PV, Pinto M, Gerashchenko BI, Narra VR, Azzam EI. Challenges and progress in predicting biological responses to incorporated radioactivity. Radiat Prot Dosimetry. 2006;122:521-527. (Pubitemid 47090518)
20. Neti PV, Howell RW. Log normal distribution of cellular uptake of radioactivity: Implications for biologic responses to radiopharmaceuticals. J Nucl Med. 2006; 47:1049-1058. (Pubitemid 46939959)
21. Neti PV, Howell RW. Lognormal distribution of cellular uptake of radioactivity: Statistical analysis of alpha-particle track autoradiography. J Nucl Med. 2008; 49:1009-1016. (Pubitemid 351793443)
22. Neti PVSV, Howell RW. Biological response to nonuniform distributions of 210Po in multicellular clusters. Radiat Res. 2007;168:332-340. (Pubitemid 351295136)
23. Durand RE. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res. 1981;41:3495-3498. (Pubitemid 11063627)
24. Luk CK, Tannock IF. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. J Natl Cancer Inst. 1989;81:55-59. (Pubitemid 19020938)
25. Kvinnsland Y, Stokke T, Aurlien E. Radioimmunotherapy with alpha-particle emitters: Microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res. 2001;155:288-296. (Pubitemid 32125979)
26. Pinto M, Howell RW. Concomitant quantification of targeted drug delivery and biological response in individual cells. Biotechniques. 2007;43:64, 66-71.
27. Aroui S, Brahim S, Waard MD, Kenani A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: A comparative study. Biochem Biophys Res Commun.2010;391:419-425.
28. Neti PV, Howell RW. When may a nonuniform distribution of 131I be considered uniform? An experimental basis for multicellular dosimetry. J Nucl Med.2003;44:2019-2026. (Pubitemid 40022148)
29. Courrol LC, Bellini MH, Tarelho LVG, et al. Urea hydrogen peroxide determination in whole blood using europium tetracycline probe. Anal Biochem.2006;355:140-144. (Pubitemid 44041411)
30. Lin Z, Wu M, SchäferlingM,Wolfbeis OS. Fluorescent imaging of citrate and other intermediates in the citric acid cycle. Angew Chem Int Ed. 2004;43:1735-1738. (Pubitemid 39257878)
31. Schäferling M, Wolfbeis OS. Europium tetracycline as a luminescent probe for nucleoside phosphates and its application to the determination of kinase activity. Chemistry. 2007;13:4342-4349. (Pubitemid 46925594)
32. Howell RW, Narra VR, Rao DV, Sastry KS. Radiobiological effects of intracellular polonium-210 alpha emissions: A comparison with Auger-emitters. Radiat Prot Dosimetry. 1990;31:325-328. (Pubitemid 20286754)
33. Goddu SM, Howell RW, Bouchet LG, BolchWE, Rao DV. MIRD Cellular S Values: Self-Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Monoenergetic Electron and Alpha Particle Emitters Incorporated into Different Cell Compartments. Reston, VA: Society of Nuclear Medicine; 1997.
34. Neti PV, Howell RW. Isolating effects of microscopic nonuniform distributions of 131I on labeled and unlabeled cells. J Nucl Med. 2004;45:1050-1058. (Pubitemid 47611692)
35. Weller M, Wiedemann P, Fischbach R, Hartmann C, Heimann K. Evaluation of daunomycin toxicity on lens epithelium in vitro. Int Ophthalmol. 1988;12: 127-130. (Pubitemid 19006695)
36. Pessina A, Piccirillo M, Mineo E, et al. Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM). Life Sci. 1999;65:513-523. (Pubitemid 29342433)
37. Krishan A, Ganapathi R. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines. Cancer Res. 1980;40:3895-3900. (Pubitemid 10030402)
38. Howell RW, Neti PV. Modeling multicellular response to nonuniform distributions of radioactivity: Differences in cellular response to self-dose and cross-dose. Radiat Res. 2005;163:216-221. (Pubitemid 40170772)
39. Costantini DL, Villani DF, Vallis KA, Reilly RM. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent 111In-NLS- trastuzumab. J Nucl Med. 2010;51:477-483.